. 2016 May 23;60(6):3309–3315. doi: 10.1128/AAC.02425-15

TABLE 2.

Median urine volume and BAL30072 concentration in urine samples of 6 male subjects of cohort 2^a

Collection period (h)	Median (range) volume (ml)	Median (range) concentration (mg/liter)	Median (range) urinary excretion (mg)
0–1^b
0–2	327 (87–1,121)	1,659 (387–6,800)	485 (218–762)
2–4	473 (83–1,012)	445 (269–3,130)	241 (206–304)
4–8	1,256 (677–1,554)	97.4 (47.8–179)	122 (59.9–233)
8–12	952 (500–2,398)	12.0 (6.09–48.9)	12.0 (5.58–30.9)
12–24	1,518 (1,059–3,456)	2.13 (1.43–6.08)	3.03 (2.24–9.42)
24–25^b
24–26	244 (125–387)	2,195 (1,510–5,600)	550 (433–700)
26–28	191 (133–693)	1,525 (430–2,280)	306 (249–363)
28–32	1,048 (775–1,136)	86.0 (58.8–170)	96.0 (45.6–168)
32–33^b
32–36	1,015 (500–1,256)	702 (582–1,090)	772 (324–1,072)
36–40	622 (412–978)	157 (92.3–358)	89.0 (72.0–148)
40–41^b
40–48	1,177 (995–1,415)	679 (523–984)	849 (573–1,025)

Subjects were administered 2 g i.v. BAL30072 over 1 h q.d. on the 1st day followed by 2 g i.v. BAL30072 over 1 h t.i.d on the 2nd day.

During this time period, 2,000 mg of i.v. BAL30072 was administered over 1 h.